The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.

lgp by the numbers
More From The Market Online

Pioneer locks in USFS approval for large-scale Springfield drilling in ‘culmination’ of prep work

Pioneer has received approval from the USFS to execute its maiden drilling program at the Springfield…

MetalsGrove Mining to test seven potential drill targets at at Zuénoula

MetalsGrove Mining is preparing to test seven news targets with auger drilling at its Zuénoula permit…

Resolution Minerals joins high-profile US defense industrial base consortium

Resolution Minerals has achieved another breakthrough in its US critical minerals strategy with its admission as…

Power’s priority mineralogy program at Morro do Ferro targeting ‘high-value’ magnet rare earth elements

Power has started a priority mineralogical characterisation program at Morro do Ferro to identify the host…